STAAR Surgical (STAA) Upgraded by BidaskClub to Strong-Buy
BidaskClub upgraded shares of STAAR Surgical (NASDAQ:STAA) from a buy rating to a strong-buy rating in a research report report published on Friday.
Other research analysts have also issued reports about the company. TheStreet raised STAAR Surgical from a c rating to a b- rating in a report on Monday, May 14th. ValuEngine raised STAAR Surgical from a hold rating to a buy rating in a report on Saturday, May 12th. Canaccord Genuity boosted their target price on STAAR Surgical from $21.00 to $23.00 and gave the stock a buy rating in a report on Thursday, May 3rd. Benchmark started coverage on STAAR Surgical in a report on Monday, August 6th. They set a buy rating and a $45.00 target price on the stock. Finally, William Blair raised STAAR Surgical from a market perform rating to an outperform rating in a report on Monday, April 30th. Four analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $38.75.
STAA stock opened at $44.80 on Friday. The company has a current ratio of 2.68, a quick ratio of 2.11 and a debt-to-equity ratio of 0.02. The company has a market cap of $1.93 billion, a P/E ratio of 4,480.00 and a beta of 1.45. STAAR Surgical has a 1-year low of $10.75 and a 1-year high of $45.65.
In related news, Director William P. Wall sold 5,000 shares of the business’s stock in a transaction on Monday, August 20th. The stock was sold at an average price of $41.35, for a total value of $206,750.00. Following the completion of the sale, the director now directly owns 16,235 shares in the company, valued at approximately $671,317.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.90% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp boosted its stake in STAAR Surgical by 20.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 197,242 shares of the medical instruments supplier’s stock valued at $6,114,000 after purchasing an additional 33,930 shares during the period. Public Employees Retirement System of Ohio bought a new stake in STAAR Surgical in the 2nd quarter valued at $3,807,000. California Public Employees Retirement System boosted its stake in STAAR Surgical by 32.2% in the 2nd quarter. California Public Employees Retirement System now owns 70,113 shares of the medical instruments supplier’s stock valued at $2,174,000 after purchasing an additional 17,066 shares during the period. Millennium Management LLC boosted its stake in STAAR Surgical by 78.0% in the 2nd quarter. Millennium Management LLC now owns 587,601 shares of the medical instruments supplier’s stock valued at $18,216,000 after purchasing an additional 257,549 shares during the period. Finally, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp bought a new stake in STAAR Surgical in the 2nd quarter valued at $896,000. Institutional investors and hedge funds own 81.91% of the company’s stock.
STAAR Surgical Company Profile
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.
Read More: What does EPS mean?
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.